Zafirlukast
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 575.68 |
Cas No. | 107753-78-6 |
Formula | C31H33N3O6S |
Solubility | ≥23.9 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O |
Chemical Name | cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate |
SDF | Download SDF |
Canonical SMILES | CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
抗菌实验 [1]: | |
细菌系 |
革兰氏阳性菌和革兰氏阴性菌 |
制备方法 |
在DMSO中的溶解度大于23.9 mg/mL。若配制更高浓度的溶液,一般步骤如下:请将试管置于37 °C加热10分钟和/或将其置于超声波浴中震荡一段时间。原液于-20 °C可放置数月。 |
反应条件 |
12.5 ~ > 100 μM |
实验结果 |
Zafirlukast对革兰氏阳性菌(包括致龋病原体S. mutans)显示出抗菌和抗生物膜活性,而对革兰氏阴性菌(除口腔病原体P. gingivalis外)没有显著活性。额外试验表明,Zafirlukast不会使S. mutans.产生耐药性。 |
动物实验 [2]: | |
动物模型 |
大鼠结肠炎模型 |
给药剂量 |
40或80 mg/kg;口服给药或直肠给药;连续3天 |
实验结果 |
在大鼠结肠炎模型中,用Zafirlukast(80 mg/kg,口服给药)进行预处理显著减少组织丙二醛和髓过氧化物酶,同时,增加减少的谷胱甘肽和过氧化氢酶水平。然而,于直肠内给予Zafirlukast没有引起显著的变化。在剂量为40 mg/kg(口服给药和直肠给药)时,没有观察到显著的保护作用。 |
注意事项 |
请于室内测试所有化合物的溶解度。虽然化合物的实际溶解度可能与其理论值略有不同,但仍处于实验系统误差的允许范围内。 |
References: [1]. Kassahun K, Skordos K, McIntosh I, Slaughter D, Doss GA, Baillie TA, Yost GS. Zafirlukast metabolism by cytochrome P450 3A4 produces an electrophilic alpha,beta-unsaturated iminium species that results in the selective mechanism-based inactivation of the enzyme. Chem Res Toxicol. 2005 Sep;18(9):1427-37. [2]. Mahgoub AA, El-Medany AA, Hager HH, Mustafa AA, El-Sabah DM. Evaluating the prophylactic potential of zafirlukast against the toxic effects of acetic acid on the rat colon. Toxicol Lett. 2003 Nov 1;145(1):79-87. |
质量控制和MSDS
- 批次: